Related Experiment Videos
[Beta-blockade--a new therapeutic modality in chronic heart insufficiency]
G Jensen1, S Boesgaard, J Aldershvile
1g.jenson@dadlnet.dk
Ugeskrift for Laeger
|October 19, 1999
Summary
Beta-blocker treatment, once contraindicated, now significantly improves survival in patients with chronic heart failure and reduced left ventricular function. This review covers the evolving evidence supporting beta-blocker use in heart failure.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Heart failure with reduced left ventricular function presents significant morbidity and mortality.
- Beta-blocker therapy was historically contraindicated for heart failure patients.
Purpose:
- To review the scientific background and evidence supporting beta-blocker treatment in chronic heart failure.
- To highlight the shift in clinical practice regarding beta-blockers for heart failure.
Summary:
- Recent major randomized trials demonstrate a significant increase in survival with beta-blocker treatment in chronic heart failure.
- Extensive research over the past two decades indicates a beneficial role for beta-blockers.
Impact:
- Beta-blocker therapy is now a cornerstone in managing chronic heart failure with reduced ejection fraction.
- This shift in treatment paradigm offers improved patient outcomes and survival rates.